A carregar...
Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
SIMPLE SUMMARY: This post-marketing research addressed the role of cyclin-dependent kinase 4/6 inhibitors, relatively new anticancer drugs approved for advanced breast cancer in cancer-associated thrombosis. We used the Food and Drug Administration pharmacovigilance database to retrospectively asses...
Na minha lista:
| Publicado no: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8067683/ https://ncbi.nlm.nih.gov/pubmed/33917020 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13081758 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|